Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug ALXN1720 aims to ease muscle weakness in myasthenia gravis

NCT ID NCT05556096

Disease control Sponsor: Alexion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether ALXN1720 can improve daily living and muscle strength in adults with generalized myasthenia gravis who have specific antibodies. About 260 participants will receive either the drug or a placebo for 26 weeks. The study is active but no longer recruiting, and results are pending.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ALXN1720
What this could lead to
If successful, ALXN1720 could offer a new treatment option to help people with generalized myasthenia gravis manage muscle weakness and improve daily activities.
What could go wrong
This is a phase 3 trial, but results are not yet available. The drug may not work better than placebo, and there are risks like infection (e.g., Neisseria meningitidis) due to its mechanism.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

260 people

The number who actually took part.

Started

Nov 2022

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of MG with generalized muscle weakness meeting the clinical criteria defined by Myasthenia Gravis Foundation of America (MGFA) Class II, III or IV * Positive serological test for autoantibodies against AChR Exclusion Criteria: * History of thymectomy, or any other thymic surgery within 12 months prior to Screening * Untreated thymic malignancy, carcinoma, or thymoma * History of Neisseria meningitidis infection * Pregnancy, breastfeeding, or intention to conceive during the course of the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Generalized myasthenia gravis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Generalized myasthenia gravis

Contacts and locations

Locations

  • Research Site

    Orange, California, 92868, United States

  • Research Site

    Fort Collins, Colorado, 80528, United States

  • Research Site

    Washington D.C., District of Columbia, 20007, United States

  • Research Site

    Bradenton, Florida, 34209, United States

  • Research Site

    Maitland, Florida, 32751, United States

  • Research Site

    Tampa, Florida, 33612, United States

  • Research Site

    Augusta, Georgia, 30912, United States

  • Research Site

    Gainesville, Georgia, 30501, United States

  • Research Site

    Savannah, Georgia, 31406, United States

  • Research Site

    Springfield, Illinois, 62769, United States

  • Research Site

    Kansas City, Kansas, 66160, United States

  • Research Site

    Lexington, Kentucky, 40503, United States

  • Research Site

    Detroit, Michigan, 48202, United States

  • Research Site

    East Lansing, Michigan, 48824, United States

  • Research Site

    Las Vegas, Nevada, 89117, United States

  • Research Site

    Patchogue, New York, 11772, United States

  • Research Site

    Rochester, New York, 14620, United States

  • Research Site

    Syracuse, New York, 13202, United States

  • Research Site

    Chapel Hill, North Carolina, 27599, United States

  • Research Site

    North Charleston, South Carolina, 29406, United States

  • Research Site

    Houston, Texas, 77030, United States

  • Research Site

    Richmond, Virginia, 23298, United States

  • Research Site

    Morgantown, West Virginia, 26506, United States

  • Research Site

    CABA, C1192AAW, Argentina

  • Research Site

    Ciudad de Buenos Aires, 1015, Argentina

  • Research Site

    Ciudad de Buenos Aires, 1181, Argentina

  • Research Site

    Ciudad de Buenos Aires, AR-CP 1221, Argentina

  • Research Site

    Rosario, S2000BZL, Argentina

  • Research Site

    Innsbruck, 6020, Austria

  • Research Site

    Wels, 4600, Austria

  • Research Site

    Barretos, 14784-400, Brazil

  • Research Site

    Joinville, 89202-190, Brazil

  • Research Site

    Porto Alegre, 90620-130, Brazil

  • Research Site

    Ribeirão Preto, 14051-140, Brazil

  • Research Site

    Salvador, 41253-190, Brazil

  • Research Site

    São José do Rio Preto, 15090-000, Brazil

  • Research Site

    São Paulo, 05403-010, Brazil

  • Research Site

    Edmonton, Alberta, T6G 2G3, Canada

  • Research Site

    Toronto, Ontario, M5G 2C4, Canada

  • Research Site

    Québec, Quebec, G1J 1Z4, Canada

  • Research Site

    Beijing, 100034, China

  • Research Site

    Beijing, 100730, China

  • Research Site

    Changchun, 130021, China

  • Research Site

    Changsha, 410008, China

  • Research Site

    Chengdu, 610041, China

  • Research Site

    Fuzhou, 350001, China

  • Research Site

    Hangzhou, 310003, China

  • Research Site

    Hangzhou, 310016, China

  • Research Site

    Jinan, 250014, China

  • Research Site

    Qingdao, 266035, China

  • Research Site

    Shanghai, 200040, China

  • Research Site

    Suzhou, 215006, China

  • Research Site

    Wuhan, 430030, China

  • Research Site

    Xi'an, 710000, China

  • Research Site

    Aalborg, 9000, Denmark

  • Research Site

    Copenhagen, 2100, Denmark

  • Research Site

    Garches, 92380, France

  • Research Site

    Lille, 59037, France

  • Research Site

    Marseille, 13385, France

  • Research Site

    Nice, 06000, France

  • Research Site

    Paris, 75651, France

  • Research Site

    Strasbourg, 67098, France

  • Research Site

    Berlin, 10117, Germany

  • Research Site

    Düsseldorf, 40225, Germany

  • Research Site

    München, 81675, Germany

  • Research Site

    Würzburg, 97074, Germany

  • Research Site

    Hadera, 38100, Israel

  • Research Site

    Haifa, 3109601, Israel

  • Research Site

    Petah Tikva, 4910000, Israel

  • Research Site

    Bergamo, 24127, Italy

  • Research Site

    Brescia, 25123, Italy

  • Research Site

    Florence, 50139, Italy

  • Research Site

    Milan, 20133, Italy

  • Research Site

    Naples, 80131, Italy

  • Research Site

    Palermo, 90127, Italy

  • Research Site

    Pisa, 56126, Italy

  • Research Site

    Roma, 00168, Italy

  • Research Site

    Rome, 00189, Italy

  • Research Site

    Chiba, 260-8677, Japan

  • Research Site

    Fukushima, 960-1295, Japan

  • Research Site

    Higashimatsuyama-shi, 355-0005, Japan

  • Research Site

    Isehara-shi, 259-1193, Japan

  • Research Site

    Itabashi-ku, 173-8610, Japan

  • Research Site

    Kawasaki-shi, 216-8511, Japan

  • Research Site

    Morioka, 020-8505, Japan

  • Research Site

    Nagasaki, 852-8501, Japan

  • Research Site

    Nagoya, 466-0065, Japan

  • Research Site

    Nagoya, 467-0001, Japan

  • Research Site

    Shinjuku-ku, 160-0023, Japan

  • Research Site

    Shinjuku-ku, 160-8582, Japan

  • Research Site

    Suita-shi, 565-0871, Japan

  • Research Site

    Amsterdam, 1105 AZ, Netherlands

  • Research Site

    Bydgoszcz, 85-086, Poland

  • Research Site

    Katowice, 40-689, Poland

  • Research Site

    Krakow, 31-202, Poland

  • Research Site

    Krakow, 31-505, Poland

  • Research Site

    Lublin, 20064, Poland

  • Research Site

    Poznan, 61-731, Poland

  • Research Site

    Almada, 2805-267, Portugal

  • Research Site

    Porto, 4099-001, Portugal

  • Research Site

    Belgrade, 11000, Serbia

  • Research Site

    Niš, 18000, Serbia

  • Research Site

    Busan, 49241, South Korea

  • Research Site

    Daegu, 41404, South Korea

  • Research Site

    Gwangju, 61469, South Korea

  • Research Site

    Seoul, 02841, South Korea

  • Research Site

    Seoul, 03722, South Korea

  • Research Site

    Seoul, 05505, South Korea

  • Research Site

    Seoul, 06351, South Korea

  • Research Site

    Seoul, 5030, South Korea

  • Research Site

    Badalona (Barcelona), 08916, Spain

  • Research Site

    Córdoba, 14004, Spain

  • Research Site

    L'Hospitalet de Llobregat, 08907, Spain

  • Research Site

    Madrid, 28034, Spain

  • Research Site

    Madrid, 28040, Spain

  • Research Site

    Madrid, 28046, Spain

  • Research Site

    Madrid, 28702, Spain

  • Research Site

    Málaga, 29010, Spain

  • Research Site

    Seville, 41009, Spain

  • Research Site

    Sankt Gallen, CH-9007, Switzerland

  • Research Site

    Kaohsiung City, 833401, Taiwan

  • Research Site

    New Taipei City, 23561, Taiwan

  • Research Site

    Tainan, 70403, Taiwan

  • Research Site

    Taipei, 11101, Taiwan

  • Research Site

    Bursa, 16059, Turkey (Türkiye)

  • Research Site

    Istanbul, 34452, Turkey (Türkiye)

  • Research Site

    Kocaeli, 41380, Turkey (Türkiye)

  • Research Site

    Samsun, 55139, Turkey (Türkiye)

  • Research Site

    Liverpool, L9 7AL, United Kingdom

  • Research Site

    London, EC1A 7BE, United Kingdom

  • Research Site

    Oxford, 0X3 7LE, United Kingdom

  • Research Site

    Sheffield, S10 2JF, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.